Konety B R, Bahnson R R
Division of Urology, University of Pittsburgh, PA, USA.
Semin Urol Oncol. 1996 Aug;14(3):183-94.
The management of stage T1b (A2) and T1c adenocarcinoma of the prostate is somewhat controversial. With the widespread use of serum prostate-specific antigen (PSA) determinations, an increasing number of these cancers are likely to be diagnosed. Hence, it is important to formulate a cogent management strategy for these patients, because a large percentage of them can be expected to have clinically and pathologically localized disease. Expectant observation with deferred treatment, radical prostatectomy, radiation therapy (external beam or brachytherapy), and cryosurgical ablation are all primary therapeutic options that have individual merit. In this review, we attempt to analyze the results of the various treatment options for these patients and evolve a practical approach towards their management.
T1b（A2）期和T1c期前列腺腺癌的治疗存在一定争议。随着血清前列腺特异性抗原（PSA）检测的广泛应用，这类癌症的诊断数量可能会增加。因此，为这些患者制定一个有说服力的治疗策略很重要，因为预计其中很大一部分患者患有临床和病理上局限的疾病。期待性观察并延迟治疗、根治性前列腺切除术、放射治疗（外照射或近距离放射治疗）以及冷冻消融都是具有各自优点的主要治疗选择。在这篇综述中，我们试图分析这些患者各种治疗选择的结果，并形成一种实用的治疗方法。
